ClinicalTrials.gg
Active, not recruitingNCT07486960Updated Oct 20, 2026

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

A Phase 2 interventional study of Tulisokibart and Placebo in Psoriatic Arthritis, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 50 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
103rd of 158
140 · median 237
Started
2026
with 7 others
Phase 2
31 of 193
3 open now
Primary completion
2027-02
later than 23 of 58 live
Registered
189th of 193
by date

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 103rd largest by planned enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2026, is one of 31 in phase 2, reaches primary completion later than 23 of the 58 other live ones, and was the 189th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA.

In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Read the detailed description

This study consists of a 16-week Placebo-controlled Period and a 112-week Long-term Extension (LTE), which is composed of a 40-week Main Extension and a 72-week Optional Extension.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.
  • Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.
  • Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response/intolerant.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA.
  • Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis.
  • Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Randomization.
  • Has any active infection.
  • Has known allergies, , or intolerance to tulisokibart of its .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    High-Dose Regimen

    Participants receive a high dose of tulisokibart.

    Drug: Tulisokibart

  • Experimental
    Medium-Dose Regimen

    Participants receive a medium dose of tulisokibart.

    Drug: Tulisokibart

  • Experimental
    Low-Dose Regimen

    Participants receive a low dose of tulisokibart and are rerandomized at Week 16 to a medium or high dose of tulisokibart.

    Drug: Tulisokibart

  • Placebo comparator
    Placebo Regimen

    Participants receive a matched placebo dose and are rerandomized at Week 16 to a medium or high dose of tulisokibart.

    Drug: Placebo

Interventions

  • Subcutaneous administration

    Also known as: MK-7240, PRA023

  • DrugPlacebo

    Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16

    ACR20 response is defined as a ≥20% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥20% improvement in ≥3 of 5 components: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) Physician Global Assessment of Disease Activity (PGA) (0= not active to 10= very active; a higher score= more active disease); iii) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) High-sensitivity C-reactive protein (hsCRP) blood values (lower value indicates less inflammation).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 16

    ACR50 response is defined as a ≥50% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥50% improvement in ≥3 of 5 components: i) HAQ-DI (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) PGA (0= not active to 10= very active; a higher score= more active disease); iii) PtGA (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) hsCRP blood values (lower value indicates less inflammation).

    Time frame: Week 16

  2. Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 16

    ACR70 response is defined as a ≥70% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥70% improvement in ≥3 of 5 components: i) HAQ-DI (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) PGA (0= not active to 10= very active; a higher score= more active disease); iii) PtGA (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) hsCRP blood values (lower value indicates less inflammation).

    Time frame: Week 16

  3. Change from Baseline in HAQ-DI Score at Week 16

    The HAQ-DI is a 20-item questionnaire that measures physical function. The questionnaire assesses the degree of difficulty a person has in accomplishing tasks in 8 functional area domains (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area domain are scored from 0 to 3 (0= without any difficulty; 3= unable to do), with a higher score indicating inability to perform activity. The overall disability score (HAQ-DI) is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3, with the higher value indicating worse disability.

    Time frame: Baseline and Week 16

  4. Number of Participants with ≥1 Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately Week 142

  5. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately Week 128

07

Study locations

50 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 9 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Aug 2027 → Feb 2027 and completion Jan 2030 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 23, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Feb 17, 2027was Aug 2027
CompletionEst.
Jul 18, 2029was Jan 2030
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Johns Hopkins University Division of Rheumatology ( Site 5132) · Baltimore, United States
  • Perelman Center for Advanced Medicine ( Site 5134) · Philadelphia, United States
Show 2 removed
  • Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center ( Site 5132) · Baltimore, United States
  • Hospital of the University of Pennsylvania ( Site 5134) · Philadelphia, United States
Oct 20, 2026
Primary completion
Aug 13, 2027→Feb 17, 2027
Oct 20, 2026
Study completion
Jan 11, 2030→Jul 18, 2029
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Johns Hopkins University Division of Rheumatology ( Site 5132) · Baltimore, United States
    • Perelman Center for Advanced Medicine ( Site 5134) · Philadelphia, United States
    Show 2 removed
    • Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center ( Site 5132) · Baltimore, United States
    • Hospital of the University of Pennsylvania ( Site 5134) · Philadelphia, United States
    Primary completion Aug 13, 2027→Feb 17, 2027
    Study completion Jan 11, 2030→Jul 18, 2029
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07486960
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Apr 20, 2026
Primary completion
Feb 17, 2027 (estimated)
Completion
Jul 18, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion